Probiotics, antibiotics and stewardship around immunotherapy
Antibiotics in the weeks before immunotherapy are linked with worse outcomes, and shop-bought probiotics may not help and might hurt. Avoiding both where possible is a low-cost precaution.
Meta-analyses of more than 10,000 patients find that antibiotic exposure within about 30-60 days before starting checkpoint inhibitors is associated with roughly halved overall survival (pooled HR near 1.9), consistent across lung, kidney and melanoma cohorts, though confounding by indication (sicker patients get antibiotics) is unresolvable in observational data. Over-the-counter probiotics were associated with lower microbiome diversity and worse response in the Spencer melanoma cohort; by contrast, the specific strain Clostridium butyricum CBM588 improved PFS when added to nivolumab-ipilimumab in a small randomised trial in kidney cancer (Nature Medicine 2022, n=30). The distinction between 'probiotics' as a class and specific evidence-based strains matters. Practical stewardship: avoid prophylactic or empirical antibiotics around IO initiation where safe, narrow spectrum and shorten courses, and counsel against unselected probiotic supplements.
How it works
Broad-spectrum antibiotics deplete the commensal taxa and metabolites that support anti-tumour immunity; generic probiotics can reduce diversity by dominating the niche, whereas specific strains may restore favourable metabolite production.
- Large, consistent observational signal for antibiotics
- Stewardship is cheap and aligns with antimicrobial resistance goals
- Randomised signal for one defined strain
- Confounding by indication in antibiotic data
- Probiotic products are unregulated and heterogeneous
- No randomised stewardship trial
Latest papers
topQuery for this technology: (TITLE:"Probiotics, antibiotics and stewardship around immunotherapy" OR ABSTRACT:"Probiotics, antibiotics and stewardship around immunotherapy") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Probiotics, antibiotics and stewardship around immunotherapy, not a curated reading list.
Pages like this
not linked directly; found by shared links- TechnologyFaecal microbiota transplantation for PD-1 non-responders
Shares Gut microbiome diversity and composition, Microbiome modulation to unlock immunotherapy, Dietary fibre and the gut microbiome for immunotherapy response, Microbiome–tumour interactions.
- TrialMIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma
Shares Gut microbiome diversity and composition, Microbiome modulation to unlock immunotherapy, Microbiome–tumour interactions, No one can predict who responds to immunotherapy.
- TrialFMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)
Shares Gut microbiome diversity and composition, Microbiome modulation to unlock immunotherapy, Microbiome–tumour interactions, No one can predict who responds to immunotherapy.
- IdeaTest a high-fibre diet as an immunotherapy adjunct
Shares Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial, Dietary fibre and the gut microbiome for immunotherapy response, No one can predict who responds to immunotherapy, Melanoma.
- PersonTasuku Honjo
Shares No one can predict who responds to immunotherapy, Nivolumab, Pembrolizumab, Melanoma.
- InstitutionCentre hospitalier de l'Université de Montréal (CHUM)
Shares Microbiome modulation to unlock immunotherapy, No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.
- IdeaRandomise a cheap antihistamine alongside immunotherapy
Shares No one can predict who responds to immunotherapy, Pembrolizumab, Melanoma, Immune checkpoint inhibitors.
- TermHallmark (2022): polymorphic microbiomes
Shares Gut microbiome diversity and composition, Dietary fibre and the gut microbiome for immunotherapy response, Microbiome–tumour interactions.